Literature DB >> 27646769

Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks.

Yuan Yu Michael Huang1, Jennifer Shuley Ruth2, Sylvia Hsu2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27646769     DOI： 10.1016/j.jaad.2016.05.049

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  5 in total

1.  Changes in metabolic parameters in psoriatic patients treated with secukinumab.

Authors:  Hsuan Ning Wang; Yu Huei Huang
Journal:  Ther Adv Chronic Dis       Date:  2020-08-03       Impact factor: 5.091

2.  Effectiveness of IL-23 Inhibitor Guselkumab in Real-World Chinese Patients with Psoriasis During a 20-Week Period.

Authors:  Yung Chan; Bik Sai Bessie Tong; Pui Yan Ngan; Chi Sum Au
Journal:  Psoriasis (Auckl)       Date:  2021-06-01

3.  Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies.

Authors:  A B Kimball; K A Papp; K Reich; M Gooderham; Q Li; N Cichanowitz; C La Rosa; A Blauvelt
Journal:  Br J Dermatol       Date:  2019-11-19       Impact factor: 9.302

4.  Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement.

Authors:  Tzong-Yun Ger; Yu-Huei Huang; Rosaline Chung-Yee Hui; Tsen-Fang Tsai; Hsien-Yi Chiu
Journal:  Ther Adv Chronic Dis       Date:  2019-04-17       Impact factor: 5.091

5.  Therapeutic drug monitoring in dermatology: the way towards dose optimization of secukinumab in chronic plaque psoriasis.

Authors:  Rani Soenen; Zhigang Wang; Lynda Grine; Erwin Dreesen; Lisa Schots; Els Brouwers; Paul Declerck; Debby Thomas; Jo Lambert
Journal:  Clin Exp Dermatol       Date:  2022-04-25       Impact factor: 4.481
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.